Uncategorized
Vertex earnings get muted investor response
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
Uncategorized
Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
Uncategorized
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
Uncategorized
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M
A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets.
🧬 Second life for a gene therapy: A Cleveland-based biotech called …
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars